Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AARD NASDAQ:RANI NASDAQ:THAR NASDAQ:TVGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAARDAardvark Therapeutics$6.73+2.1%$4.96$3.35▼$17.94$143.77M5.11136,082 shs158,052 shsRANIRani Therapeutics$1.11+5.7%$1.02$0.39▼$3.87$129.88M0.74765,979 shs1.58 million shsTHARTharimmune$3.51+7.3%$3.56$0.95▼$9.08$132.43M1.431.48 million shs641,247 shsTVGNTevogen Bio$9.42+39.1%$6.36$4.14▼$75.50$28.19M0.0919,330 shs176,492 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAARDAardvark Therapeutics+2.12%+20.18%+45.04%-44.38%-23.00%RANIRani Therapeutics+5.71%+19.23%+32.57%-10.48%+99.35%THARTharimmune+7.34%+9.69%+17.59%-21.65%+150.71%TVGNTevogen Bio+39.14%+25.94%+57.53%-32.71%-82.87%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAARDAardvark Therapeutics$6.73+2.1%$4.96$3.35▼$17.94$143.77M5.11136,082 shs158,052 shsRANIRani Therapeutics$1.11+5.7%$1.02$0.39▼$3.87$129.88M0.74765,979 shs1.58 million shsTHARTharimmune$3.51+7.3%$3.56$0.95▼$9.08$132.43M1.431.48 million shs641,247 shsTVGNTevogen Bio$9.42+39.1%$6.36$4.14▼$75.50$28.19M0.0919,330 shs176,492 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAARDAardvark Therapeutics+2.12%+20.18%+45.04%-44.38%-23.00%RANIRani Therapeutics+5.71%+19.23%+32.57%-10.48%+99.35%THARTharimmune+7.34%+9.69%+17.59%-21.65%+150.71%TVGNTevogen Bio+39.14%+25.94%+57.53%-32.71%-82.87%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAARDAardvark Therapeutics 2.54Moderate Buy$22.20229.87% UpsideRANIRani Therapeutics 2.67Moderate Buy$7.80602.70% UpsideTHARTharimmune 1.00SellN/AN/ATVGNTevogen Bio 1.50Reduce$100.00961.57% UpsideCurrent Analyst Ratings BreakdownLatest TVGN, THAR, RANI, and AARD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026AARDAardvark Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingEqual Weight ➝ Underweight$7.00 ➝ $3.005/13/2026AARDAardvark Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/29/2026AARDAardvark Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/20/2026TVGNTevogen Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/14/2026RANIRani Therapeutics Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$9.004/1/2026RANIRani Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$9.00 ➝ $5.003/27/2026AARDAardvark Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026RANIRani Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026RANIRani Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.003/24/2026AARDAardvark Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.003/4/2026TVGNTevogen Bio D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAARDAardvark TherapeuticsN/AN/AN/AN/A$3.99 per shareN/ARANIRani Therapeutics$1.63M84.23N/AN/A$0.34 per share3.26THARTharimmuneN/AN/AN/AN/A$0.68 per shareN/ATVGNTevogen BioN/AN/AN/AN/A($211.84) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAARDAardvark Therapeutics-$57.59M-$3.21N/AN/AN/AN/A-61.71%-56.29%N/ARANIRani Therapeutics-$29.67M-$0.59N/AN/AN/AN/A-774.04%-106.02%5/15/2026 (Estimated)THARTharimmune-$12.20M-$3.99N/AN/AN/AN/A-588.45%-264.41%6/3/2026 (Estimated)TVGNTevogen Bio-$26.27M-$9.50N/AN/AN/AN/AN/A-610.37%5/15/2026 (Estimated)Latest TVGN, THAR, RANI, and AARD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026RANIRani Therapeutics-$0.06N/AN/AN/A$1.13 millionN/A5/15/2026N/ATVGNTevogen Bio-$2.00N/AN/AN/AN/AN/A5/7/2026Q1 2026AARDAardvark TherapeuticsN/A-$0.99N/A-$0.99N/AN/A3/26/2026Q4 2025RANIRani Therapeutics-$0.03-$0.07-$0.04-$0.07$5.00 million$1.46 million3/23/2026Q4 2025AARDAardvark Therapeutics-$0.81-$0.81N/A-$0.81N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAARDAardvark TherapeuticsN/AN/AN/AN/AN/ARANIRani TherapeuticsN/AN/AN/AN/AN/ATHARTharimmuneN/AN/AN/AN/AN/ATVGNTevogen BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAARDAardvark TherapeuticsN/A8.068.06RANIRani TherapeuticsN/A4.214.21THARTharimmuneN/A4.984.98TVGNTevogen BioN/A0.220.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAARDAardvark TherapeuticsN/ARANIRani Therapeutics30.19%THARTharimmune1.16%TVGNTevogen BioN/AInsider OwnershipCompanyInsider OwnershipAARDAardvark TherapeuticsN/ARANIRani Therapeutics26.51%THARTharimmune6.70%TVGNTevogen Bio70.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAARDAardvark Therapeutics1821.82 millionN/AN/ARANIRani Therapeutics110123.69 million90.90 millionOptionableTHARTharimmune237.73 million35.20 millionNot OptionableTVGNTevogen Bio34.16 million1.23 millionN/ATVGN, THAR, RANI, and AARD HeadlinesRecent News About These CompaniesTevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest ...May 12 at 12:58 PM | caledonianrecord.comCTevogen Bio Holdings Inc. Secures $3 Million PIPE Financing from The Patel Family, LLPMay 12 at 11:50 AM | quiverquant.comQTevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market CloseMay 12 at 11:45 AM | globenewswire.comTevogen Bio (TVGN) to Release Quarterly Earnings on FridayMay 8, 2026 | americanbankingnews.comTevogen (TVGN) Soars 11% as Firm Gears Up for AI Training CommercializationMay 5, 2026 | finance.yahoo.comTevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application PortalApril 27, 2026 | finance.yahoo.comTevogen.AI Nears Completion of PredicTcellâ„¢ Training; Initiates Commercial Readiness and Debuts Internal Application PortalApril 27, 2026 | globenewswire.comTevogen Bio krijgt melding van Nasdaq wegens niet-naleving beursregelsApril 23, 2026 | nl.investing.comTevogen Bio Faces Nasdaq Market Value Compliance ChallengesApril 22, 2026 | tipranks.comTevogen Bio Holdings (TVGN) price target increased by 1,900.00% to 102.00March 27, 2026 | msn.comTevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and ...March 26, 2026 | caledonianrecord.comCTevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue GrowthMarch 26, 2026 | globenewswire.comTevogen Bio Regains Nasdaq Compliance After Reverse SplitMarch 25, 2026 | tipranks.comTevogen Bio Holdings Regains Compliance with Nasdaq Listing RequirementsMarch 25, 2026 | quiverquant.comQTevogen Regains Compliance with Nasdaq Minimum Bid Price RequirementMarch 25, 2026 | globenewswire.comTevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)March 18, 2026 | markets.businessinsider.comTevogen Bio Holdings Inc. Announces CIO Mittul Mehta to Speak at Microsoft Fabric Community Conference 2026 on Data Engineering and AIMarch 18, 2026 | quiverquant.comQTevogen Bio Inc: Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share UtilizationMarch 14, 2026 | finanznachrichten.deTevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share UtilizationMarch 13, 2026 | globenewswire.comTevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI InfrastructureMarch 13, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026NVIDIA's Quantum Computing Play Just Sent IonQ and Rigetti Flying By Jeffrey Neal Johnson | April 15, 20263 Overlooked Nuclear Fuel Supply Chain WinnersBy Nathan Reiff | April 26, 2026Atomic Dividends: Big Tech's New Energy BetBy Jeffrey Neal Johnson | May 5, 2026TVGN, THAR, RANI, and AARD Company DescriptionsAardvark Therapeutics NASDAQ:AARD$4.34 -2.25 (-34.20%) As of 09:30 AM Eastern This is a fair market value price provided by Massive. Learn more.Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.Rani Therapeutics NASDAQ:RANI$1.12 +0.07 (+6.57%) As of 09:30 AM Eastern This is a fair market value price provided by Massive. Learn more.Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.Tharimmune NASDAQ:THAR$3.51 +0.24 (+7.34%) As of 05/13/2026Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.Tevogen Bio NASDAQ:TVGN$8.85 +2.08 (+30.78%) As of 09:30 AM Eastern This is a fair market value price provided by Massive. Learn more.Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies 2 Ways to Play the Big Pharma Patent Cliff Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
